Eshleman SH - Search Results

1

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).

Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH. Gulick RM, et al. Among authors: eshleman sh. J Infect Dis. 2017 Jan 15;215(2):238-246. doi: 10.1093/infdis/jiw525. J Infect Dis. 2017. PMID: 27811319 Free PMC article. Clinical Trial.

2

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Eshleman SH, et al. J Infect Dis. 2001 Jun 15;183(12):1732-8. doi: 10.1086/320728. Epub 2001 May 16. J Infect Dis. 2001. PMID: 11372025 Clinical Trial.

3

Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB. Eshleman SH, et al. J Infect Dis. 2001 Oct 1;184(7):914-7. doi: 10.1086/323153. Epub 2001 Aug 13. J Infect Dis. 2001. PMID: 11509999 Clinical Trial.

4

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Kashuba AD, et al. Among authors: eshleman sh. AIDS. 2005 Jan 28;19(2):145-52. doi: 10.1097/00002030-200501280-00006. AIDS. 2005. PMID: 15668539 Clinical Trial.

5

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

Flys T, Nissley DV, Claassen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH. Flys T, et al. Among authors: eshleman jr, eshleman sh. J Infect Dis. 2005 Jul 1;192(1):24-9. doi: 10.1086/430742. Epub 2005 Jun 1. J Infect Dis. 2005. PMID: 15942890

6

Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. Eshleman SH, et al. J Infect Dis. 2005 Jul 1;192(1):30-6. doi: 10.1086/430764. Epub 2005 Jun 1. J Infect Dis. 2005. PMID: 15942891

7

Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, Jackson JB, Kumwenda NI, Taha TE. Eshleman SH, et al. J Infect Dis. 2006 Feb 15;193(4):479-81. doi: 10.1086/499967. Epub 2006 Jan 11. J Infect Dis. 2006. PMID: 16425125

8

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Mayer KH, et al. Among authors: eshleman sh. AIDS. 2006 Feb 28;20(4):543-51. doi: 10.1097/01.aids.0000210608.70762.c3. AIDS. 2006. PMID: 16470118 Clinical Trial.

9

Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naive Malawian women.

Eshleman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, Petropoulos CJ, Kumwenda N, Parkin N, Taha TE. Eshleman SH, et al. J Infect Dis. 2006 Jun 1;193(11):1512-5. doi: 10.1086/503810. Epub 2006 Apr 20. J Infect Dis. 2006. PMID: 16652278

10

Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.

Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH. Flys TS, et al. Among authors: eshleman sh. J Infect Dis. 2007 Mar 1;195(5):711-5. doi: 10.1086/511433. Epub 2007 Jan 18. J Infect Dis. 2007. PMID: 17262714 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

262 results

Search Page